Aspire NZ Seed Fund (Aspire) is proud to back Marama Labs as they develop cutting-edge instrumentation through the launch of CloudSpec in nanomedicine. Their patented technology dramatically shortens the time it takes to quantify drug payloads in Lipid Nanoparticle (LNP) formulations, from hours down to seconds. This leap in efficiency could unlock faster, more scalable development of next-generation therapies across gene editing, vaccines, and oncology. Congratulations to the Marama team for this milestone!
🚨 CloudSpec is officially launched and commercially available! 🚨 After a year of extensive validation with some of the world’s leading mRNA producers, CloudSpec is now out in the world, and ready to transform how scientists quantify lipid nanoparticle (LNP) payloads. 🧬 Gene therapies, mRNA vaccines, cancer treatments — LNPs are powering them all. But analysing their RNA or DNA payloads has been a major bottleneck. CloudSpec changes that. ⚡ 15-second measurements ⚡ No dyes ⚡ No breaking particles ⚡ Results you can trust Developed with input from top-tier biopharma partners, CloudSpec is already helping teams move faster, with more confidence. 🎙️ Join our webinar on May 7 to hear from two early CloudSpec users: Dr. Emily Young (4basebio) and Dr. Johanna Simon (Merck KGaA) 👉 https://lnkd.in/eR8Hg44Z 💻 More on CloudSpec: www.maramalabs.com 📽️ Launch video: https://lnkd.in/evS2-Sci This is a huge milestone for us, and a major step forward for the mRNA/LNP field. https://lnkd.in/e6MdA9Ak